Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...3233343536373839404142...5960»
  • ||||||||||  dexamethasone / Generic mfg.
    [VIRTUAL] Pleurihormonal Pituitary Adenomas Presenting as Acromegaly () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_3319;    
    Lab results showed elevated cortisol value of 8.4 mcg/dl after 1 mg dexamethasone suppression test... This Cushing's predominant case of a GH-ACTH co-secreting tumor is an incredibly rare presentation for this pleurihormonal pituitary adenoma, which is already a rare diagnosis.
  • ||||||||||  dexamethasone / Generic mfg.
    [VIRTUAL] A Rare Case of a Plurihormonal Pituitary Adenoma () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_3317;    
    The patient underwent workup for Cushing's Disease with a low dose overnight dexamethasone suppression test, resulting in an appropriate response with an 8 AM cortisol of <1.0 ug/dL...For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
  • ||||||||||  [VIRTUAL] Acromegaly Management: Exploring the Therapeutic Landscape () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_3011;    
    The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021. There is no abstract associated with this presentation.
  • ||||||||||  [VIRTUAL] CMES08. Acromegaly: Novel Therapeutic Options to Alleviate Treatment Burden and Improve Patient Quality of Life () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_3009;    
    There is no abstract associated with this presentation. Join us for a discussion of: Strategies to improve patient recognition and diagnosis based on the pathophysiology and clinical symptomology of acromegaly - Common comorbidities associated with acromegaly and the burden on patient quality of life despite endocrine control - Recent clinical evidence regarding the safety and efficacy of currently approved and emerging treatment options for the management of patients with acromegaly - The importance of continued monitoring of patients with acromegaly and improved provider-patient communication to ensure symptom control and minimizing the treatment burden and QoL burden
  • ||||||||||  [VIRTUAL] Meet the Professor () -  Mar 27, 2021 - Abstract #ENDO2021ENDO_2937;    
    A number of complications however appear less effected by GH status, including obstructive sleep apnoea, arthropathy, and quality of life. The greatest benefit to reducing these complications is likely to be earlier diagnosis and rapid control of GH and IGF-I excess.
  • ||||||||||  Journal:  From dwarves to giants: South American's contribution to the history of growth hormone and related disorders. (Pubmed Central) -  Mar 17, 2021   
    Additionally, we have reviewed the exceptional work carried out in two of the world's largest cohorts of dwarfism related to GH-IGF axis: one living in Itabaianinha, Brazil, suffering from severe GHD due to a mutation in the GHRH receptor (GHRHR) gene, and the other living in El Oro and Loja provinces of Ecuador, who are carriers of GH receptor gene mutation that causes total GH insensitivity (Laron syndrome). Importantly, we present an overview of the outstanding medical contribution of Jose Dantas de Souza Leite, a Brazilian physician that described the first cases of acromegaly, and Bernardo Alberto Houssay, an Argentine researcher graced with the Nobel Prize, who was one the first scientists to establish a link between GH and glucose metabolism.
  • ||||||||||  Journal:  Emerging drugs for the treatment of Acromegaly. (Pubmed Central) -  Mar 17, 2021   
    The constant progresses in the medical treatment of acromegaly could lead to an individualized therapy based on tumor, as well as patient's characteristics. Besides disease control, patient's need represents a major target of medical treatment in chronic diseases such as acromegaly, in order to improve compliance to therapy and patients' quality of life.
  • ||||||||||  Review, Journal:  Endocrine Causes of Hypertension. (Pubmed Central) -  Mar 12, 2021   
    Endocrine causes of hypertension are multifactorial and, in some cases, widely prevalent. It is important for clinicians considering secondary causes of hypertension to be knowledgeable about the underlying pathophysiology of these disorders and to understand when additional evaluation and treatment may be needed.
  • ||||||||||  Clinical, Journal:  Impact of concurrent diabetes on periodontal health in patients with acromegaly. (Pubmed Central) -  Mar 9, 2021   
    Nevertheless, the patients with acromegaly having diabetes had modestly higher CAL and PD and serum IL-6 levels (p = 0.051), but it could not exert adverse effects on periodontal health in presence of GH/IGF1 excess. GH/IGF1 excess did not exert a protective effect on periodontal status in acromegaly, possibly due to concurrent hypogonadism and opposing cytokines; however, it could mask the ill-effects of diabetes on periodontal health.
  • ||||||||||  Biomarker, Journal:  The ElonginB/C-Cullin5-SOCS-Box-Complex Is a Potential Biomarker for Growth Hormone Disorders. (Pubmed Central) -  Mar 7, 2021   
    SOCS2 showed the best individual diagnostic performance with an overall accuracy of 0.93, while the combination of the three proteins correctly identified all patients and controls. This resulted in perfect sensitivity and specificity for all patient groups, which demonstrates potential benefits of the ECS-complex proteins as clinical biomarkers for the diagnostics of GH-related diseases and substantiates their important role in GH metabolism.
  • ||||||||||  Journal:  Acromegaly and it's cardiovascular implications (Pubmed Central) -  Mar 6, 2021   
    Frequently, the cardiovascular comorbidities of acromegaly occur concomitantly with metabolic complications such as diabetes and respiratory abnormalities such as the sleep apnea syndrome. In this brief review we analyze the pathophysiology, the clinical manifestations and the management of the cardiovascular complications of acromegaly.
  • ||||||||||  metformin / Generic mfg.
    Observational data, Journal:  Possible protective role of metformin therapy on colonic polyps in acromegaly: an exploratory cross-sectional study. (Pubmed Central) -  Mar 2, 2021   
    Multivariate analysis confirmed a significant negative association between colonic polyps and metformin intake (OR: 0.22, 95% CI: 0.06-0.77, P = 0.01), whereas no significant association was found between polyps and age (P = 0.10), overweight/obesity (P = 0.54), smoking (P = 0.15), acetylsalicylic acid intake (P = 0.99), disease duration (P = 0.96), somatostatin analogues treatment (P = 0.70). These findings, though deriving from an exploratory study, could suggest a protective role of metformin on the development of colonic polyps in acromegaly, and need to be confirmed in an extended study population.
  • ||||||||||  Journal:  Molecular profiling confirms historical immunohistochemistry in acromegaly. (Pubmed Central) -  Feb 27, 2021   
    These findings, though deriving from an exploratory study, could suggest a protective role of metformin on the development of colonic polyps in acromegaly, and need to be confirmed in an extended study population. No abstract available
  • ||||||||||  bromocriptine / Generic mfg.
    [VIRTUAL] DO WE NEED A PITUITARY DISEASES REGISTRY IN LATVIA? () -  Feb 24, 2021 - Abstract #ICE2021ICE_474;    
    Based on the study of the pituitary disease registry in Latvia, a unified database of pituitary diseases pts has been created. A state founded registry may be set up in the future.
  • ||||||||||  [VIRTUAL] NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIOS IN PITUITARY ADENOMAS () -  Feb 24, 2021 - Abstract #ICE2021ICE_465;    
    This study evaluated, for the first time to the knowledge of the authors, the behavior of inflammatory markers in the composition of the complete blood count test in patients with prolactinomas and NFA, and extended the evaluation of these markers in acromegalics, subject of rare reports in the literature. The significance of high individual NLR and/or PLR rates in patients with pituitary adenomas requires new and extended analysis to establish their clinical relevance
  • ||||||||||  [VIRTUAL] PREVALENCE OF ANEMIA IN A BRAZILIAN COHORT OF MEN AND WOMEN WITH PITUITARY ADENOMAS () -  Feb 24, 2021 - Abstract #ICE2021ICE_464;    
    The found values are twice the prevalence found in the adult Brazilian population, which is 9.9%. These results improve knowledge of the epidemiological profile of pituitary adenomas patients in terms of hematimetric parameters; and suggest the need to expand studies in the area with the assessment of clinical and hormonal variables with a possible impact on the establishment of anemia.